October 2022 – CROss Alliance® would like to congratulate our colleagues at Sintetica SA for the brilliant achievement obtained with the early FDA approval of IHEZOO™, a revolutionary ophthalmic gel for ocular surface anesthesia.

CROSS is proud to have contributed to the clinical product development, and to have delivered high-quality services, despite the challenging pandemic period when those clinical activities have been performed.

We look forward to achieving further successes together!

Read full Sintetica’s article at: Early approval of our ophtalmic gel by the FDA (sintetica.com)